Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

57
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
57
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

59
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
59
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

62
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
62
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.6K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.6K
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

3.2K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.2K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

853
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
853

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oxidative stress and anxiety-like symptoms related to withdrawal of passive cigarette smoke in mice: beneficial effects of pecan nut shells extract, a by-product of the nut industry.

Ecotoxicology and environmental safety·2011
Same author

Is chronic hepatitis B being undertreated in the United States?

Journal of viral hepatitis·2010
Same author

The combination of hyperthyroidism and pernicious anemia; report of a case with a review of the literature.

Annals of internal medicine·2010
Same author

Alterations in capillary permeability in meningeal irritations; an aid to differential diagnosis.

The American journal of the medical sciences·2010
Same author

Clinical manifestations in forty cases of myxedema.

The Journal of clinical endocrinology and metabolism·2010
Same author

Current status of the field of cardiovascular nuclear medicine.

Seminars in nuclear medicine·1999

Related Experiment Video

Updated: Feb 26, 2026

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
09:37

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique

Published on: September 23, 2022

2.3K

Reversible common variable immunodeficiency syndrome induced by phenytoin.

M Travin1, N T Macris, J M Block

  • 1Department of Medicine, Lenox Hill Hospital, New York, NY 10021.

Archives of Internal Medicine
|June 1, 1989
PubMed
Summary

Phenytoin can cause a rare condition called panhypogammaglobulinemia, mimicking common variable immunodeficiency. Stopping phenytoin therapy allowed immunoglobulin levels to normalize in a patient with recurrent infections.

More Related Videos

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype
08:49

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

11.7K
Phenotypic and Functional Analysis of Activated Regulatory T Cells Isolated from Chronic Lymphocytic Choriomeningitis Virus-infected Mice
07:17

Phenotypic and Functional Analysis of Activated Regulatory T Cells Isolated from Chronic Lymphocytic Choriomeningitis Virus-infected Mice

Published on: June 22, 2016

10.4K

Related Experiment Videos

Last Updated: Feb 26, 2026

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
09:37

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique

Published on: September 23, 2022

2.3K
Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype
08:49

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

11.7K
Phenotypic and Functional Analysis of Activated Regulatory T Cells Isolated from Chronic Lymphocytic Choriomeningitis Virus-infected Mice
07:17

Phenotypic and Functional Analysis of Activated Regulatory T Cells Isolated from Chronic Lymphocytic Choriomeningitis Virus-infected Mice

Published on: June 22, 2016

10.4K

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by low immunoglobulin levels and recurrent infections.
  • Phenytoin is an anticonvulsant medication with known side effects, but drug-induced immunodeficiency is uncommon.

Observation:

  • A patient on phenytoin and corticosteroid therapy developed panhypogammaglobulinemia, recurrent pneumonia, eosinophilia, and a transient rash.
  • Pre-treatment immunoglobulin levels were normal, but decreased significantly during phenytoin therapy.

Findings:

  • Phenytoin-induced panhypogammaglobulinemia was diagnosed, presenting similarly to CVID.
  • Immunoglobulin levels normalized within months after discontinuing phenytoin.
  • Eosinophilia and rashes were noted, consistent with other reported cases of phenytoin-induced immune dysfunction.

Implications:

  • Phenytoin therapy can rarely lead to acquired hypogammaglobulinemia, necessitating careful immunologic monitoring.
  • Clinicians should consider phenytoin as a potential cause of hypogammaglobulinemia, especially in patients with recurrent infections, eosinophilia, or rashes.
  • This case highlights the importance of drug history in diagnosing immunodeficiency syndromes.